Inventor · disambiguated record
Pangke Yan
Also filed as: YAN PANGKE
6 granted patents·39 pending applications·10 citations·filing 2015–2025
73Inventor score
Files withXIZANG HAISCO PHARMACEUTICAL CO LTD26SICHUAN HAISCO PHARMACEUTICAL CO LTD12HAISCO PHARMACEUTICALS PTE LTD5HAISCO PHARMACEUTICAL GROUP CO LTD2
Top patents by PatentIndex Score
45 records- 0192US11807635B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2022·Granted Nov 7, 2023·5 cites·12 claims
- 0286US11542266B1Substituted piperidines as BTK inhibitorsHAISCO PHARMACEUTICALS PTE LTD·Filed 2021·Granted Jan 3, 2023·3 cites·19 claims
- 0375US11014964B2Peptide amide compound and preparation method and medical use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2018·Granted May 25, 2021·2 cites·13 claims
- 0474US12365673B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2023·Granted Jul 22, 2025·0 cites·6 claims
- 0568US2025340555A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0668US2025372228A1Method and system for determining population pharmacokinetic model of propofol and derivative thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0767US2025059186A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0865US2023343418A1Method and system for determining population pharmacokinetic model of propofol and derivative thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0962US2025263426A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1061US2025326765A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1159US2025171436A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1259US2025145627A1METTL3 Inhibitor and Composition, and Application of Same in MedicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1359US2025340532A1Heterocyclic compound ccr4 inhibitor and user thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1459US2024383917A1Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1558US2025000988A1Epha2 bicyclic peptide ligand and conjugate thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1658US2025346571A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1757US2025195485A1Propionic acid derivative and medical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1857US2025333410A1Compound for inhibiting or degrading bcl6 and use thereof in pharmaceuticsXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1956US2024391937A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2056US2024208932A1Arylamino derivative estrogen receptor modulator and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2156US2024043416A1Salt and crystal form of ha inhibitor compoundSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2256US2025034168A1Nitrogen-containing heterocyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2356US2025382289A1Pyrazolopyridine derivative and application thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2455US2024067633A1Ketohexokinase inhibitor and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2555US2025222116A1Parp-1 degradation agent and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2655US2024343720A1Aak1 inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2755US2025084101A1Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2854US2024124470A1Five-membered ring derivative and medical use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2954US2024368204A1Small molecular cd73 antagonist and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3053US2025215008A1Preparation and use of quinazolinone derivative as kinase inhibitorHAISCO PHARMACEUTICAL GROUP CO LTD·Filed 2023·Application pending·0 cites
- 3153US2023265107A1Pb2 inhibitor, and preparation method therefor and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3253US2025171417A1Heterocyclic derivative, and composition and pharmaceutical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3352US2024317736A1Deuterated derivative as atx inhibitor, and application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3452US2024400586A1Heteroaryl derivative parp inhibitor and use thereofHAISCO PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
- 3551US2024408085A1Compound for degradation of bcl-2 family proteins and medical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3651US2024018147A1Salt of compound for degrading btk, crystal form thereof, and use thereof in medicineHAISCO PHARMACEUTICALS PTE LTD·Filed 2021·Application pending·0 cites
- 3750US2023248833A1Compound having btk kinase degrading activity, and preparation method and pharmaceutical use thereforSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3850US2024269298A1Phosphonyl derivative, and composition and pharmaceutical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3949US2023357193A1Compound capable of inhibiting and degrading androgen receptors, and pharmaceutical compositions and pharmaceutical uses thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4049US2023069174A1Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4149US2024383874A1Benzene ring derivative, and composition and pharmaceutical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4249US2023365541A1Inhibitor of enhancer of zeste homologue 2, and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2021·Application pending·0 cites
- 4348US2023079045A1Anti-influenza virus compound, preparation method and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4445US12226381B2Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 18, 2025·0 cites·11 claims
- 4532US10729666B2Use of GABAA receptor reinforcing agent in preparation of sedative and anesthetic medicamentSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2015·Granted Aug 4, 2020·0 cites·54 claims
Join the waitlist — get patent alerts
Get an alert when Pangke Yan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →